Home / Healthcare / Premature Ejaculation - Pipeline Review, H2 2015

Premature Ejaculation - Pipeline Review, H2 2015

Published: Nov 2015 | No Of Pages: 53 | Published By: Global Markets Direct

Premature Ejaculation - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Premature Ejaculation - Pipeline Review, H2 2015', provides an overview of the Premature Ejaculation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Premature Ejaculation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Ejaculation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Premature Ejaculation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Premature Ejaculation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Premature Ejaculation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Premature Ejaculation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Premature Ejaculation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Premature Ejaculation Overview 6
Therapeutics Development 7
Pipeline Products for Premature Ejaculation - Overview 7
Premature Ejaculation - Therapeutics under Development by Companies 8
Premature Ejaculation - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Premature Ejaculation - Products under Development by Companies 12
Premature Ejaculation - Companies Involved in Therapeutics Development 13
Allergan Plc 13
NeuroHealing Pharmaceuticals Inc. 14
Plethora Solutions Holdings Plc 15
SK Chemicals Co., Ltd. 16
Premature Ejaculation - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles (lidocaine + prilocaine) - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
(tramadol hydrochloride + PDE-5 Inhibitor) - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
IX-01 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
modafinil - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NCE-405 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
onabotulinumtoxin A - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
tramadol hydrochloride - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Premature Ejaculation - Recent Pipeline Updates 39
Premature Ejaculation - Dormant Projects 45
Premature Ejaculation - Discontinued Products 46
Premature Ejaculation - Product Development Milestones 47
Featured News & Press Releases 47
Jan 08, 2015: Vyrix Pharmaceuticals to Present at Biotech Showcase 2015 47
Nov 11, 2014: Plethora Solutions Provides Company Update 47
Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU 47
Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment 48
Mar 11, 2014: Plethora Solutions Provides Company update 49
Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation 49
Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation 50
Jul 01, 2013: AGM Statement & PSD502 Regulatory Update 50
Jun 03, 2013: Ampio Pharma Provides Update On Sexual Dysfunction Portfolio 51
Mar 11, 2013: Ampio Receives FDA Acceptance Of Patient Outcome For Premature Ejaculation Questionnaire Paving Way For US Pivotal Trial On Zertane 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

Number of Products under Development for Premature Ejaculation, H2 2015 7
Number of Products under Development by Companies, H2 2015 8
Comparative Analysis by Late Stage Development, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Comparative Analysis by Early Stage Development, H2 2015 11
Products under Development by Companies, H2 2015 12
Premature Ejaculation - Pipeline by Allergan Plc, H2 2015 13
Premature Ejaculation - Pipeline by NeuroHealing Pharmaceuticals Inc., H2 2015 14
Premature Ejaculation - Pipeline by Plethora Solutions Holdings Plc, H2 2015 15
Premature Ejaculation - Pipeline by SK Chemicals Co., Ltd., H2 2015 16
Assessment by Monotherapy Products, H2 2015 17
Assessment by Combination Products, H2 2015 18
Number of Products by Stage and Target, H2 2015 20
Number of Products by Stage and Mechanism of Action, H2 2015 22
Number of Products by Stage and Route of Administration, H2 2015 24
Number of Products by Stage and Molecule Type, H2 2015 26
Premature Ejaculation Therapeutics - Recent Pipeline Updates, H2 2015 39
Premature Ejaculation - Dormant Projects, H2 2015 45
Premature Ejaculation - Discontinued Products, H2 2015 46

Number of Products under Development for Premature Ejaculation, H2 2015 7
Number of Products under Development by Companies, H2 2015 8
Comparative Analysis by Late Stage Development, H2 2015 9
Assessment by Monotherapy Products, H2 2015 17
Assessment by Combination Products, H2 2015 18
Number of Products by Targets, H2 2015 19
Number of Products by Stage and Targets, H2 2015 19
Number of Products by Mechanism of Actions, H2 2015 21
Number of Products by Stage and Mechanism of Actions, H2 2015 21
Number of Products by Routes of Administration, H2 2015 23
Number of Products by Stage and Routes of Administration, H2 2015 23
Number of Products by Molecule Types, H2 2015 25
Number of Products by Stage and Molecule Types, H2 2015 25

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +